Molina (NYSE: MOH) to record $93M impairment and eases loan covenant

Rhea-AI Filing Summary

Molina Healthcare, Inc. amended its credit agreement on February 4, 2026, temporarily easing a key debt covenant. The required minimum quarterly interest coverage ratio was reduced from 3.00:1.00 to 1.75:1.00 for quarters ending March 31 through December 31, 2026, then stepped up to 2.00:1.00 for March 31, 2027, 2.50:1.00 for June 30, 2027, and 2.75:1.00 for September 30, 2027.

The company also determined on February 5, 2026 that it will record an estimated non-cash, pre-tax impairment charge of approximately $93 million in the first quarter of 2026, tied to certain intangible assets. This follows a decision to exit its Medicare Advantage Prescription Drug product for 2027 to focus exclusively on dual eligible Medicare members. The charge will be recorded outside of adjusted net income.

Positive

• None.

Negative

• Estimated $93 million impairment charge: Molina Healthcare will record a non-cash, pre-tax impairment of approximately $93 million in Q1 2026 related to certain intangible assets, reducing reported pre-tax income for that period.
• Reduced interest coverage covenant: The minimum quarterly interest coverage ratio is temporarily lowered from 3.00:1.00 to as low as 1.75:1.00 through 2026, indicating a need for greater flexibility under the company’s credit agreement.

Insights

Credit and healthcare services analyst

Covenant relief and a $93M impairment reflect financial and strategic pressure.

Molina Healthcare obtained temporary covenant relief by amending its credit agreement, lowering the minimum interest coverage ratio from 3.00:1.00 to as low as 1.75:1.00 through December 31, 2026, then gradually increasing it through September 30, 2027. This suggests lenders agreed to more flexibility around interest coverage while maintaining a clear step-up schedule.

The company also expects an estimated non-cash, pre-tax impairment charge of about $93 million in Q1 2026, related to certain intangible assets. This stems from exiting its Medicare Advantage Prescription Drug product for 2027 to focus on dual eligible Medicare members. While non-cash, the charge reduces reported pre-tax income for the period, though it will be excluded from adjusted net income as defined in the referenced earnings materials.

The combination of a sizable impairment and relaxed interest coverage requirements points to a meaningful strategic realignment with measurable accounting impact. Subsequent filings may provide more detail on financial performance under the revised covenant thresholds and the ongoing Medicare dual-eligible strategy.

false 0001179929 0001179929 2026-02-04 2026-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K 

______________

Current Report

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2026 (February 4, 2026)

______________

MOLINA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-31719			13-4204626
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

______________

200 Oceangate, Suite 100, Long Beach, California			Long Beach,			California			90802
(Address of principal executive offices)									(Zip Code)

Registrant’s telephone number, including area code: (562) 435-3666

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 Par Value			MOH			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On February 4, 2026, Molina Healthcare, Inc. (the “Company”) entered into a First Amendment to its Credit Agreement (the “Amended Credit Agreement”) among the Company, as the Borrower, the Lenders (as defined therein) party thereto, and Truist Bank, as Administrative Agent. The Amended Credit Agreement amends the Company’s prior Credit Agreement dated as of November 20, 2025 (the “Prior Credit Agreement”). The terms of the Amended Credit Agreement are substantially similar to the terms of the Prior Credit Agreement, except that Section 6.2 was revised to temporarily reduce the quarterly required minimum interest coverage ratio from 3.00:1.00 to (a) with respect to each fiscal quarter ending March 31, 2026 through and including December 31, 2026, 1.75:1.00, (b) with respect to fiscal quarter ending March 31, 2027, 2.00:1.00, (c) with respect to fiscal quarter ending June 30, 2027, 2.50:1.00, and (d) with respect to fiscal quarter ending September 30, 2027, 2.75:1.00.

The foregoing summary of the Amended Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amended Credit Agreement, a copy of which is being filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Amended Credit Agreement is incorporated by reference into this Item 2.03.

Item 2.06. Material Impairments

On February 5, 2026, the Company concluded that it will record in the first quarter of 2026 an estimated non-cash, pre-tax impairment charge of approximately $93 million, attributable to certain of its intangible assets. This impairment charge results from the Company’s decision to exit the Medicare Advantage Prescription Drug product for 2027 as that product does not align with the Company’s strategic shift to focus exclusively on dual eligible members in Medicare. This charge will be recorded outside of adjusted net income. “Adjusted net income” is defined in the Company’s fourth quarter earnings release issued on February 5, 2026, and included as an exhibit to the Form 8-K filed on that same date.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.	Description
10.1	First Amendment to Credit Agreement, dated as of February 4, 2026, by and among Molina Healthcare, Inc., as the Borrower, Truist Bank, As Administrative Agent, and the Lenders party thereto
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLINA HEALTHCARE, INC.
Date: February 6, 2026	By:	/s/ Jeff Barlow
		Jeff Barlow.
		Chief Legal Officer and Secretary

FAQ

What major financial charge did Molina Healthcare (MOH) disclose?

Molina Healthcare expects an estimated non-cash, pre-tax impairment charge of about $93 million in the first quarter of 2026. The charge relates to certain intangible assets and will be recorded outside of the company’s adjusted net income measure.

Why is Molina Healthcare recording a $93 million impairment charge?

The impairment stems from Molina Healthcare’s decision to exit its Medicare Advantage Prescription Drug product for 2027. The company is shifting strategy to focus exclusively on dual eligible Medicare members, reducing the value of related intangible assets.

How did Molina Healthcare change its credit agreement covenants?

Molina Healthcare’s amended credit agreement temporarily reduces the quarterly minimum interest coverage ratio from 3.00:1.00 to 1.75:1.00 for quarters ending March 31 through December 31, 2026, then gradually increases it through the quarter ending September 30, 2027.

Over what period is Molina Healthcare’s interest coverage ratio relief in effect?

The reduced minimum interest coverage ratio applies from the quarter ending March 31, 2026 through the quarter ending September 30, 2027. It starts at 1.75:1.00 and steps up to 2.00:1.00, 2.50:1.00, and finally 2.75:1.00.

How will the $93 million impairment affect Molina Healthcare’s adjusted net income?

Molina Healthcare states the approximately $93 million non-cash, pre-tax impairment charge will be recorded outside of adjusted net income. This means it will lower GAAP earnings but will be excluded from the company’s adjusted net income metric.

What strategic shift did Molina Healthcare announce in connection with the impairment?

The company decided to exit its Medicare Advantage Prescription Drug product for 2027. Molina Healthcare’s strategy is to focus exclusively on dual eligible members in Medicare, aligning operations and reported intangible asset values with this narrower focus.